Carisma Therapeutics, Inc.Carisma Therapeutics, Inc.Carisma Therapeutics, Inc.

Carisma Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−0.43USD
Revenue estimate
‪4.40 M‬USD
Market capitalization
‪68.13 M‬USD
−3.47USD
‪−86.88 M‬USD
‪14.92 M‬USD
‪19.35 M‬
Beta (1Y)
2.14

About Carisma Therapeutics, Inc.

CEO
Steven Kelly
Headquarters
Philadelphia
Employees (FY)
107
Founded
2016
FIGI
BBG001J2N453
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CARM is 1.64 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Carisma Therapeutics, Inc. stocks are traded under the ticker CARM.
Carisma Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
CARM stock is 6.25% volatile and has beta coefficient of 2.14. Check out the list of the most volatile stocks — is Carisma Therapeutics, Inc. there?
CARM earnings for the last quarter are −0.53 USD per share, whereas the estimation was −0.57 USD resulting in a 7.02% surprise. The estimated earnings for the next quarter are −0.55 USD per share. See more details about Carisma Therapeutics, Inc. earnings.
Carisma Therapeutics, Inc. revenue for the last quarter amounts to ‪3.83 M‬ USD despite the estimated figure of ‪1.19 M‬ USD. In the next quarter revenue is expected to reach ‪2.91 M‬ USD.
Yes, you can track Carisma Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
CARM stock has fallen by 3.53% compared to the previous week, the month change is a 28.38% fall, over the last year Carisma Therapeutics, Inc. has showed a 58.90% decrease.
CARM net income for the last quarter is ‪−20.96 M‬ USD, while the quarter before that showed ‪−21.40 M‬ USD of net income which accounts for 2.08% change. Track more Carisma Therapeutics, Inc. financial stats to get the full picture.
Today Carisma Therapeutics, Inc. has the market capitalization of ‪68.13 M‬, it has increased by 10.00% over the last week.
Like other stocks, CARM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Carisma Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
CARM reached its all-time high on Feb 26, 2014 with the price of 386.65 USD, and its all-time low was 1.53 USD and was reached on Apr 19, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 27, 2024, the company has 107.00 employees. See our rating of the largest employees — is Carisma Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Carisma Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Carisma Therapeutics, Inc. stock shows the sell signal. See more of Carisma Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Carisma Therapeutics, Inc. future price: according to them, CARM price has a max estimate of 12.00 USD and a min estimate of 6.00 USD. Read a more detailed Carisma Therapeutics, Inc. forecast: see what analysts think of Carisma Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Carisma Therapeutics, Inc. EBITDA is ‪−84.53 M‬ USD, and current EBITDA margin is −539.35%. See more stats in Carisma Therapeutics, Inc. financial statements.